BETA CELL TECHNOLOGIES

Our vision is to find a cure for type 1 diabetes
Our

Inspiration


Type 1 Diabetes Mellitus (T1D), either as the primary disease or its multi-system complications, is one of the largest burdens on health services globally. It is a serious, life-long autoimmune disease that usually occurs in childhood but can be diagnosed at any age. T1D occurs when the pancreas does not produce enough insulin (a hormone that regulates blood sugar, or glucose), due to the immune system destroying insulin-producing beta cells within the pancreas. T1D is an increasing public health problem, because both the number of cases and the prevalence of the disease have been steadily increasing over the past few decades.

Read More

Our

Technology


Beta Cell has identified an opportunity to design, develop and implement a novel Intracutaneous Ectopic Pancreas (IEP) to treat T1D on a local, national and global scale. The pioneering treatment consists of seeding human Islets of Langerhans into an integrated Biodegradable Temporising Matrix (NovoSorb®BTM). At this site, the cells survive whilst being nurtured within the highly vascularised and loosely-woven collagen structure which develops inside the NovoSorb®BTM. This is an ideal site for the seeding of human cells to produce ectopic organs in the skin, because establishment of the IEP, monitoring and analysis of structure and function, and complete IEP removal are facilitated. Beta Cell has patents in Australia, the United States and Europe.

Read More

Latest

News


our Partners